Assembly Biosciences Doses First Participant In Phase 1a/b Trial Of HSV Inhibitor ABI-5366
Portfolio Pulse from Benzinga Newsdesk
Assembly Biosciences has dosed the first participant in its Phase 1a/b trial of HSV inhibitor ABI-5366. The Phase 1a study involves single ascending doses in healthy participants, with interim data expected in Q3 2024. The Phase 1b study will involve multiple ascending weekly doses in participants with recurrent genital herpes, with interim data expected in the first half of 2025.
June 10, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Assembly Biosciences has initiated dosing in its Phase 1a/b trial for HSV inhibitor ABI-5366. Interim data for Phase 1a is expected in Q3 2024, and for Phase 1b in the first half of 2025.
The initiation of the Phase 1a/b trial and the expected interim data timelines are positive developments for Assembly Biosciences. This progress could boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100